THE WOODLANDS, Texas,
Aug. 10, 2012 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that
Arthur Sands, M.D., Ph.D., President
and Chief Executive Officer, will present at the Wedbush PacGrow
2012 Life Sciences Management Access Conference on Tuesday, August 14th, at 10:55 AM EST in New
York City. Dr. Sands will provide an overview of Lexicon's
clinical development programs and milestones.
A webcast of the presentation will be available through
Lexicon´s website at www.lexpharma.com. An archived version of the
presentation will be available at www.lexpharma.com until
September 14th, 2012.
About Lexicon
Lexicon is a biopharmaceutical company focused on
discovering breakthrough treatments for human disease. Lexicon
currently has four drug programs in mid-stage development for
diabetes, carcinoid syndrome, irritable bowel syndrome and
rheumatoid arthritis, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout
technology to identify more than 100 promising drug targets.
Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking"
statements, including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct preclinical and clinical
development of its potential drug candidates, advance additional
candidates into preclinical and clinical development, obtain
necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates, that may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2011, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.